Doctronic Raises $40M to Bring AI-Powered Primary Care to Everyone

Americans now wait an average of 31 days to see a doctor. That is the longest wait on record. For millions of people, that gap between need and access translates into delayed diagnoses, unmanaged chronic conditions, and preventable deteriorations in health. Doctronic, an AI doctor startup, was built specifically to close that gap, and it is now doing so at a scale that few predicted was possible this quickly. The company has announced a $40 million Series B funding round co-led by Abstract and Lightspeed Venture Partners, with participation from prior investors and new backers Wittington Ventures and ARTIS Ventures. The round brings Doctronic’s total funding to $65 million, raised across three rounds in under a year.

From Startup to World’s Most-Used AI Doctor in Under a Year

Doctronic’s ascent has been remarkably fast by any measure. Founded in 2023, the company only began offering services with human clinicians in January 2025. By the time of this funding announcement, it had already completed more than 24 million AI consultations, making it the most widely used AI doctor platform in the world, not just in the United States, but globally. The company is now on track to generate more than $10 million in revenue this year, a trajectory that reflects both strong organic demand for its service and the structural inadequacy of the healthcare access problem it is solving.

The company is backed by an impressive roster of investors. Earlier rounds drew participation from Union Square Ventures, Tusk Venture Partners, and HF0, and the Series B adds two of the most prominent names in venture capital, Lightspeed Venture Partners and Abstract, to that group. The broad participation across rounds from leading healthcare and technology investors signals that Doctronic is viewed not as a niche consumer product but as a genuine infrastructure play in the future of primary care delivery.

How Doctronic Works?

Doctronic’s model is designed around the reality that most people encounter healthcare passively, waiting for symptoms to become serious enough to justify the friction of booking an appointment, taking time off work, and navigating an insurance system that can still leave them with significant out-of-pocket costs. Doctronic removes that friction entirely. Users begin with a free AI doctor consultation, available 24 hours a day, seven days a week, covering a wide range of primary care concerns from symptom checking and diagnosis to women’s health, dermatology, weight management, and urology.

The AI component of the platform is trained exclusively on peer-reviewed medical sources. Its treatment plans have been independently verified to align with those of board-certified clinicians 99.2 percent of the time, a figure that compares favourably with the diagnostic accuracy of many human primary care encounters. For cases that require a prescription, a referral, or a direct clinical assessment, Doctronic connects users with licensed physicians available via video visit across all 50 states and Washington D.C., for a fee of $39. The AI does the preparation work, collecting symptom history, organising health information, and generating a clinical summary, so the human doctor can focus on decision-making rather than information gathering.

The platform is also the first AI in the United States to be legally authorised to offer prescription renewals, a milestone it has already put into practice in Utah, where AI prescription renewals are live across 190 medications. This is not a cosmetic capability. It addresses a genuine bottleneck in the healthcare system, where patients with stable, well-managed conditions are often required to schedule in-person or telehealth appointments purely to renew prescriptions that have not changed, consuming clinical time and patient resources that could be better spent elsewhere.

Privacy, Compliance, and the Question of Trust

For any AI system operating in healthcare, trust is the central challenge. Doctronic addresses this directly. The platform is HIPAA-compliant and can be used entirely anonymously. The company’s stated policy is that user data is never used to train AI models, never sold, and never shared with third parties. Users who create accounts retain full ownership of their health data. This approach reflects an understanding that the willingness of patients to share sensitive health information with an AI depends entirely on confidence that it will be handled with the same discretion expected of a human clinician.

The company has also taken a forthright approach to the limitations of its technology. Doctronic is transparent that its AI, while highly accurate, does make mistakes, and consistently recommends that its output be discussed with a licensed human doctor. Far from undermining confidence in the platform, this honesty is likely a significant factor in its rapid adoption. In a category where overclaiming is common, Doctronic’s measured framing positions it as a credible partner in healthcare rather than a replacement for clinical judgment.

What $40 Million Will Fund?

Doctronic has been clear about its plans for the Series B capital. The immediate priority is scaling the engineering and product teams to keep pace with growth that has outrun expectations even by the company’s own assessment. The longer-term priority is building out partnership infrastructure with health systems, insurance payers, and digital health companies, extending Doctronic’s reach beyond direct-to-consumer into the institutional channels that serve the broadest possible patient populations.

This institutional expansion signals a shift in ambition. A direct-to-consumer AI doctor serving individuals willing to pay $39 for a telehealth visit is a meaningful business. A platform integrated into health systems and insurance networks, conducting triage, managing chronic conditions, handling prescription renewals, and routing patients to appropriate levels of care, is a fundamental piece of healthcare infrastructure. That is the direction Doctronic appears to be heading, and the calibre of investors now backing the company suggests there is serious conviction that it can get there.

A Pivotal Moment for AI in Healthcare

Doctronic’s Series B arrives at a moment when the question of how AI should be used in clinical care is moving from theoretical to urgently practical. The company is preparing for its first meeting with the FDA, a development that will have significant implications for how the broader industry understands the regulatory pathway for AI-powered clinical tools. The outcome of that engagement will be watched closely not just by Doctronic’s investors but by every health system, insurer, and AI developer considering how to deploy intelligent technology in patient-facing settings.

What Doctronic has demonstrated in under a year is that the demand for accessible, affordable, high-quality primary care is enormous and largely unmet by the existing system. Twenty-four million consultations completed is not a pilot programme result. It is evidence of a structural need that the traditional model of healthcare delivery has failed to address. With $65 million now behind it, a globally recognised platform, and institutional partnerships beginning to take shape, Doctronic is well positioned to move from being the world’s most-used AI doctor to being one of the most consequential companies in the future of global healthcare.